Yoganathan Sangeetha, Sudhakar SniyaVALSA, Thomas Maya, Kumar Dutta Atanu, Danda Sumita, Chandran Mahalakshmi
Department of Pediatrics Neurology Sciences, Christian Medical College, Tamil Nadu, India.
Department of Pediatrics Radiology, Christian Medical College, Tamil Nadu, India.
Iran J Child Neurol. 2018 Spring;12(2):107-112.
Molybdenum cofactor deficiency is a rare metabolic disorder manifesting with early onset seizures, developmental delay, microcephaly, and spasticity. In this report, we describe a three-month-old infant with neonatal onset, poorly controlled seizures, developmental delay, microcephaly, spastic quadriparesis and visual insufficiency. Magnetic resonance imaging of brain had shown cystic encephalomalacia involving bilateral parieto-occipital lobe and elevated lactate in magnetic resonance spectroscopy. Restricted diffusion noted along the corticospinal tract in our case is a novel imaging finding in patients with molybdenum cofactor deficiency. Low serum uric acid and elevated urine sulfite excretion were observed. A novel homozygous mutation was detected in exon 4 of molybdenum cofactor synthesis 2 () gene. Early infantile or neonatal onset seizures, developmental delay, microcephaly and cystic encephalomalacia in neuroimaging mimicking hypoxic-ischaemic encephalopathy should raise the suspect for molybdenum cofactor deficiency. Screening of all neonates for urinary sulfite metabolites would help in early diagnosis and management. Early diagnosis and treatment with cyclic pyranopterin monophosphate could arrest the progression of molybdenum cofactor deficiency type A. More research is needed to explore further treatment options in this otherwise lethal disorder.
钼辅因子缺乏症是一种罕见的代谢紊乱疾病,表现为早发性癫痫发作、发育迟缓、小头畸形和痉挛。在本报告中,我们描述了一名3个月大的婴儿,其新生儿期起病,癫痫发作控制不佳,伴有发育迟缓、小头畸形、痉挛性四肢瘫和视力不足。脑部磁共振成像显示双侧顶枕叶出现囊性脑软化,磁共振波谱显示乳酸水平升高。在我们的病例中,沿皮质脊髓束观察到的扩散受限是钼辅因子缺乏症患者的一种新的影像学表现。观察到血清尿酸水平低和尿亚硫酸盐排泄增加。在钼辅因子合成2()基因的第4外显子中检测到一个新的纯合突变。对于神经影像学表现为类似缺氧缺血性脑病的早发性或新生儿期癫痫发作、发育迟缓、小头畸形和囊性脑软化,应怀疑钼辅因子缺乏症。对所有新生儿进行尿亚硫酸盐代谢物筛查将有助于早期诊断和治疗。早期使用环磷酸吡哆醛进行诊断和治疗可阻止A型钼辅因子缺乏症的进展。对于这种否则会致命的疾病,需要进行更多研究以探索进一步的治疗选择。